The Lancet Diabetes & Endocrinology最新文献

筛选
英文 中文
Correction to Lancet Diabetes Endocrinol 2025; 13: 175–76
IF 44.5 1区 医学
The Lancet Diabetes & Endocrinology Pub Date : 2025-03-08 DOI: 10.1016/s2213-8587(25)00065-8
{"title":"Correction to Lancet Diabetes Endocrinol 2025; 13: 175–76","authors":"","doi":"10.1016/s2213-8587(25)00065-8","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00065-8","url":null,"abstract":"<em>Beran D, Bandini A, Bosi E, et al. Type 1 diabetes screening: need for ethical, equity, and health systems perspective.</em> Lancet Diabetes Endocrinol <em>2025;</em> 13: <em>175–76</em>—In this Correspondence, the spelling of author Marie-Anne Burckhardt's name was incorrect. This correction has been made to the online version as of March 6, 2025.","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"38 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143576109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The promise and pitfalls of “Make America Healthy Again”
IF 44.5 1区 医学
The Lancet Diabetes & Endocrinology Pub Date : 2025-03-06 DOI: 10.1016/s2213-8587(25)00060-9
Lindsey Smith Tallie, Barry Popkin
{"title":"The promise and pitfalls of “Make America Healthy Again”","authors":"Lindsey Smith Tallie, Barry Popkin","doi":"10.1016/s2213-8587(25)00060-9","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00060-9","url":null,"abstract":"No Abstract","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"25 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143569363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A step towards more physiological glucocorticoid dosing in congenital adrenal hyperplasia
IF 44.5 1区 医学
The Lancet Diabetes & Endocrinology Pub Date : 2025-03-06 DOI: 10.1016/s2213-8587(25)00033-6
Martin Reincke
{"title":"A step towards more physiological glucocorticoid dosing in congenital adrenal hyperplasia","authors":"Martin Reincke","doi":"10.1016/s2213-8587(25)00033-6","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00033-6","url":null,"abstract":"No Abstract","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"86 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143569364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: a retrospective cohort study
IF 44.5 1区 医学
The Lancet Diabetes & Endocrinology Pub Date : 2025-03-05 DOI: 10.1016/s2213-8587(24)00371-1
Babak J Orandi, Yusi Chen, Yiting Li, Garyn T Metoyer, Krista L Lentine, Michael Weintraub, Sunjae Bae, Nicole M Ali, Bonnie E Lonze, Christine J Ren-Fielding, Holly Lofton, Akash Gujral, Dorry L Segev, Mara McAdams-DeMarco
{"title":"GLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: a retrospective cohort study","authors":"Babak J Orandi, Yusi Chen, Yiting Li, Garyn T Metoyer, Krista L Lentine, Michael Weintraub, Sunjae Bae, Nicole M Ali, Bonnie E Lonze, Christine J Ren-Fielding, Holly Lofton, Akash Gujral, Dorry L Segev, Mara McAdams-DeMarco","doi":"10.1016/s2213-8587(24)00371-1","DOIUrl":"https://doi.org/10.1016/s2213-8587(24)00371-1","url":null,"abstract":"&lt;h3&gt;Background&lt;/h3&gt;Given the cardiovascular, renal, and survival benefits of GLP-1 receptor agonists for diabetes, these agents could be effective among kidney transplant recipients. However, kidney transplant recipients are distinct from GLP-1 receptor agonist trial participants, with longer diabetes duration and severity, greater end-organ damage, increased cardiovascular risk, and multimorbidity. We examined GLP-1 receptor agonist real-world effectiveness and safety in kidney transplant recipients with diabetes.&lt;h3&gt;Methods&lt;/h3&gt;This USA-based retrospective cohort study included kidney transplant recipients with type 2 diabetes at transplantation and Medicare as their primary insurance from a national registry linked with Medicare claims. Post-transplantation GLP-1 receptor agonist use was identified through Medicare claims. Death-censored graft loss was estimated using the Fine-Gray sub-distribution hazard model and extended Cox models were used for mortality and safety endpoints. Models incorporated inverse probability of treatment weights. To further test whether bias could affect the main results, a cohort was created in which each GLP-1 receptor agonist user was matched with a kidney transplant recipient who had not started a GLP-1 receptor agonist, was alive with a functioning graft, and had accrued the same amount of post-transplant survival time.&lt;h3&gt;Findings&lt;/h3&gt;Between Jan 1, 2013 and Dec 31, 2020, we identified 44 536 first time kidney transplant recipients with Medicare as primary payer in the 6 months before and at transplantation. 24 192 patients were excluded as they did not have type 2 diabetes. 2328 patients were ineligible (1916 had missing values and 412 used GLP-1 receptor agonists before transplantation). The primary cohort thus consisted of 18 016 kidney transplant recipients with diabetes. Of these patients, 1969 (10·9%) had at least one GLP-1 receptor agonist prescription filled post-transplant. Compared with patients who had not received a GLP-1 receptor agonist, GLP-1 receptor agonist users were younger (median age at transplant 57 years [IQR 49–64] &lt;em&gt;vs&lt;/em&gt; 60 years [51–66], p&lt;0·0001) and more likely to be female (786 [39·9%] &lt;em&gt;vs&lt;/em&gt; 5645 [35·2%], p&lt;0·0001). Among GLP-1 receptor agonist users, 552 [28·0%] were non-Hispanic White, 703 [35·7%] were non-Hispanic Black, and 568 [28·8%] were Hispanic. The 5-year unadjusted cumulative incidence of death-censored graft loss from a cohort matched on survival time before GLP-1 receptor agonist initiation was 6·0% for GLP-1 receptor agonist users and 10·7% for non-users (Gray's test p=0·004). The 5-year unadjusted cumulative incidence for mortality from a cohort matched on survival time before GLP-1 receptor agonist initiation was 17·0% for GLP-1 receptor agonist users and 25·8% for non-users (log-rank p=0·0006). The 5-year unadjusted cumulative incidence for mortality was 13·5% for GLP-1 receptor agonist users and 19·9% for non-users (log-rank p&lt;0·0001). GLP-1 re","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"4 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143560790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to Lancet Diabetes Endocrinol 2024; 12: e2–11
IF 44.5 1区 医学
The Lancet Diabetes & Endocrinology Pub Date : 2025-03-05 DOI: 10.1016/s2213-8587(25)00056-7
{"title":"Correction to Lancet Diabetes Endocrinol 2024; 12: e2–11","authors":"","doi":"10.1016/s2213-8587(25)00056-7","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00056-7","url":null,"abstract":"<em>Emerging Risk Factors Collaboration/EPIC-CVD/Vitamin D Studies Collaboration. Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses.</em> Lancet Diabetes Endocrinol <em>2024;</em> 12: <em>e2–11</em>—The appendix of this Article has been corrected as of March 5, 2025.","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"16 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143560930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What does renal failure teach us about our National Health System?
IF 44.5 1区 医学
The Lancet Diabetes & Endocrinology Pub Date : 2025-03-05 DOI: 10.1016/s2213-8587(25)00059-2
Angelo Avogaro
{"title":"What does renal failure teach us about our National Health System?","authors":"Angelo Avogaro","doi":"10.1016/s2213-8587(25)00059-2","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00059-2","url":null,"abstract":"No Abstract","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"30 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143560792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GLP-1 receptor agonists: even for kidney transplant recipients with pre-existing diabetes?
IF 44.5 1区 医学
The Lancet Diabetes & Endocrinology Pub Date : 2025-03-05 DOI: 10.1016/s2213-8587(24)00399-1
Monica Cortinovis, Norberto Perico, Giuseppe Remuzzi
{"title":"GLP-1 receptor agonists: even for kidney transplant recipients with pre-existing diabetes?","authors":"Monica Cortinovis, Norberto Perico, Giuseppe Remuzzi","doi":"10.1016/s2213-8587(24)00399-1","DOIUrl":"https://doi.org/10.1016/s2213-8587(24)00399-1","url":null,"abstract":"No Abstract","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"67 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143560791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial
IF 44.5 1区 医学
The Lancet Diabetes & Endocrinology Pub Date : 2025-02-28 DOI: 10.1016/s2213-8587(24)00377-2
Takashi Kadowaki, Arihiro Kiyosue, Tomotaka Shingaki, Tomonori Oura, Koutaro Yokote
{"title":"Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial","authors":"Takashi Kadowaki, Arihiro Kiyosue, Tomotaka Shingaki, Tomonori Oura, Koutaro Yokote","doi":"10.1016/s2213-8587(24)00377-2","DOIUrl":"https://doi.org/10.1016/s2213-8587(24)00377-2","url":null,"abstract":"&lt;h3&gt;Background&lt;/h3&gt;Data on tirzepatide in Asian patients with obesity are limited. This study aimed to gain a better understanding of tirzepatide for treatment of Japanese patients with obesity disease (BMI ≥25 kg/m&lt;sup&gt;2&lt;/sup&gt; with excessive fat accumulation) as defined by the Japanese Society for the Study of Obesity.&lt;h3&gt;Methods&lt;/h3&gt;This was a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial of the efficacy and safety of tirzepatide as an adjunct to lifestyle modifications. Japanese adults with obesity disease (BMI ≥27 kg/m&lt;sup&gt;2&lt;/sup&gt; accompanied by ≥2 obesity-related health disorders or ≥35 kg/m&lt;sup&gt;2&lt;/sup&gt; accompanied by ≥1 obesity-related health disorders), excluding diabetes, were assigned 1:1:1 via computer-generated random sequence to receive once weekly subcutaneous tirzepatide (10 mg or 15 mg) or placebo. Coprimary endpoints were the mean percent change in bodyweight and the proportion of participants achieving at least 5% bodyweight reduction at week 72, using the efficacy estimand. Efficacy and safety were assessed in the modified intention-to-treat (mITT) population. This study is registered with &lt;span&gt;&lt;span&gt;ClinicalTrials.gov&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;, &lt;span&gt;&lt;span&gt;NCT04844918&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;.&lt;h3&gt;Findings&lt;/h3&gt;Between May 10, 2021, and June 24, 2023, 413 participants were screened, and 267 were randomly assigned. Due to exclusion of one study site, the mITT population was 225 participants (133 [59%] men and 92 [41%] women, mean age 50·8 [SD 10·7] years), with 73 in the tirzepatide 10 mg group, 77 in the tirzepatide 15 mg group, and 75 in the placebo group, of whom 192 (85%) completed both study and treatment. Estimated treatment differences relative to placebo in change in bodyweight at week 72 were −16·1% (95% CI −18·7 to −13·5; p&lt;0·0001) and −21·1% (95% CI −23·6 to −18·5; p&lt;0·0001) following tirzepatide 10 mg and 15 mg, respectively. At week 72, a higher proportion of participants achieved at least 5% bodyweight reduction with tirzepatide 10 mg (67 [94%] of 71) and 15 mg (73 [96%] of 76) compared with placebo (15 [20%] of 75; both p&lt;0·0001). Cardiometabolic and body composition indices were also improved with tirzepatide. Participants treated with tirzepatide experienced treatment-emergent adverse events more frequently (10 mg: n=61 [84%]; 15 mg: n=66 [86%]) than those who received placebo (52 [69%]), most commonly gastrointestinal symptoms. Study discontinuations due to adverse events were infrequent (placebo: n=3 [4%]; tirzepatide 10 mg: n=1 [1%]; tirzepatide 15 mg: n=0).&lt;h3&gt;Interpretation&lt;/h3&gt;In Japanese adults with obesi","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"1 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143526431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Promising treatment options with tirzepatide for Japanese individuals with obesity disease 日本肥胖症患者使用替扎帕肽的治疗方案前景广阔
IF 44.5 1区 医学
The Lancet Diabetes & Endocrinology Pub Date : 2025-02-28 DOI: 10.1016/s2213-8587(25)00024-5
Michael A Nauck, Soo Lim
{"title":"Promising treatment options with tirzepatide for Japanese individuals with obesity disease","authors":"Michael A Nauck, Soo Lim","doi":"10.1016/s2213-8587(25)00024-5","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00024-5","url":null,"abstract":"No Abstract","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"33 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143526429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bodyweight loss and remission of type 2 diabetes
IF 44.5 1区 医学
The Lancet Diabetes & Endocrinology Pub Date : 2025-02-26 DOI: 10.1016/s2213-8587(24)00373-5
Andreas L Birkenfeld, Michael Bergman
{"title":"Bodyweight loss and remission of type 2 diabetes","authors":"Andreas L Birkenfeld, Michael Bergman","doi":"10.1016/s2213-8587(24)00373-5","DOIUrl":"https://doi.org/10.1016/s2213-8587(24)00373-5","url":null,"abstract":"No Abstract","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"25 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143507052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信